BioVie’s Stock Plummets 33% Following SUNRISE-PD Phase IIb Trial Data Release Utilizing Novel, Company-Created EPNIC-15 Endpoint
Executive Overview In the high-stakes world of biopharmaceutical research, the line separating scientific innovation from investor skepticism is razor-thin. On August 6, clinical-stage biotechnology company BioVie learned this lesson firsthand…